Cardiovascular Disease

Levels of angiotensin-converting enzyme 2 vary significantly in patients who are given angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Individuals taking angiotensin-converting enzyme inhibitors typically have reduced angiotensin-converting enzyme-2 levels. Angiotensin-converting enzyme-2 levels show a notable positive correlation with the female gender. Angiotensin-converting enzyme 2 (ACE2) is one of the major enzymes of the renin–angiotensin–aldosterone...

Heart disease is a terrifying medical issue that kills around 697,000 Americans each year. Because of this, preventing heart disease is a top issue for many.  However, the possibility of a genetic condition adds a hurdle to this. If heart disease is genetic, can it truly be managed?  This article will explore the genetic nature...

Heart disease is one of the leading causes of death for adults in America and is something many people live with for the rest of their lives. With this in mind, it is understandable to question if it can be reversed. After all, the ability to do so would dramatically improve lives while simultaneously improving...

Patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) are at risk of cardiovascular comorbidities, including atrial fibrillation and flutter. Routine ambulatory monitoring in patients with ATTR-CM could help drive the use of anticoagulation to prevent strokes. Heart complications, such as heart failure, are common in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM). Atrial fibrillation and flutter (AF/AFL), in...

The awareness and diagnosis of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is challenging, despite ATTRwt being more common than previously thought. Screening is necessary for early detection and diagnosis of ATTRwt CM, as well as for timely treatment of the disease. The clinical characteristics of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) can vary among affected...

Heart failure, among other cardiovascular problems, is a typical manifestation of transthyretin amyloidosis cardiomyopathy (ATTR-CM). The prevalence of ATTR-CM as a phenotype of heart failure is often underestimated. Heart failure with preserved ejection fraction (HFpEF) affects more than half of patients with heart failure. The phenotypes of heart failure can vary, and treatment modalities are...

Medication adherence is a critical aspect of treating patients with ATTR-CM and ensuring optimal outcomes. Research suggests that many patients with ATTR-CM are adherent to treatment with tafamidis, partly due to the availability of a one-tablet dose. Tafamidis is the first FDA-approved treatment for ATTR-CM that has been shown to help reduce disease progression and...

An early diagnosis of transthyretin amyloidosis (ATTR) is key for managing the disease and preventing costly complications. One study suggests that cardiovascular symptoms and increased hospitalizations are a potential way to identify the disease early. Transthyretin amyloidosis (ATTR) is a progressive condition characterized by the buildup of amyloid in the organs and tissues. It can...

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are faced with different possibilities for treating their symptoms and underlying disease. However, treatment options may vary depending on the severity of the disease, the cost of the treatment, and other factors. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive disease that primarily affects the heart, although it can...